Chemical Structure (B581d63f 61cb 41b6 A7ca 24bd0b32a8ae 01)
Zanaflex
Product Images NDC 21695-373
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Zanaflex (NDC 21695-373). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Graph 1 (B581d63f 61cb 41b6 A7ca 24bd0b32a8ae 02)
Graph 2 (B581d63f 61cb 41b6 A7ca 24bd0b32a8ae 03)
Graph 3 (B581d63f 61cb 41b6 A7ca 24bd0b32a8ae 04)
The text describes the improvement in Ashworth Score for a study of Tizanidine. The study lasted 7 weeks and had a titration phase that lasted for 3 weeks. The mean dose used was 26.8 mg. The improvement in Ashworth Score was measured at the end of titration, end of maintenance, and at the endpoint of the study.*
Zanaflex 4mg (B581d63f 61cb 41b6 A7ca 24bd0b32a8ae 05)
This is a product description of Zanaflex 4mg capsules, containing 30 capsules per pack. Each capsule has 4mg of Tizanidine Hydrochloride equivalent to 4mg Tizanidine base. The product ID is PZ037330. No other information is available.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
